Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Comprehensive Study Of The Clinical Phenotype Of Germline BAP1 Variant-Carrying Families Worldwide

S. Walpole, A. Pritchard, C. Cebulla, R. Pilarski, Meredith Stautberg, F. Davidorf, A. de la Fouchardière, O. Cabaret, L. Golmard, D. Stoppa-Lyonnet, E. Garfield, C. Njauw, M. Cheung, J. Turunen, P. Repo, Reetta-Stiina Järvinen, R. van Doorn, M. Jager, Gregorius P M Luyten, M. Marinkovic, Cindy Chau, M. Potrony, V. Höiom, H. Helgadottir, L. Pastorino, W. Bruno, V. Andreotti, B. Dalmasso, G. Ciccarese, P. Queirolo, L. Mastracci, K. Wadt, J. Kiilgaard, M. Speicher, Natasha M van Poppelen, E. Kiliç, Rana'a T. Al-Jamal, I. Dianzani, M. Betti, C. Bergmann, S. Santagata, S. Dahiya, S. Taibjee, J. Burke, N. Poplawski, S. O'Shea, J. Newton-Bishop, J. Adlard, D. Adams, Anne-Marie Lane, I. Kim, S. Klebe, H. Racher, J. Harbour, M. Nickerson, R. Murali, J. Palmer, Madeleine Howlie, J. Symmons, H. Hamilton, Sunil K. Warrier, W. Glasson, P. Johansson, C. D. Robles-Espinoza, Raul Ossio, A. de Klein, S. Puig, P. Ghiorzo, M. Nielsen, T. Kivelä, H. Tsao, J. Testa, Pedram Gerami, M. Stern, B. B. Paillerets, M. Abdel-Rahman, N. Hayward
Published 2018 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Background The BRCA1-associated protein-1 (BAP1) tumor predisposition syndrome (BAP1-TPDS) is a hereditary tumor syndrome caused by germline pathogenic variants in BAP1 encoding a tumor suppressor associated with uveal melanoma, mesothelioma, cutaneous melanoma, renal cell carcinoma, and cutaneous BAP1-inactivated melanocytic tumors. However, the full spectrum of tumors associated with the syndrome is yet to be determined. Improved understanding of the BAP1-TPDS is crucial for appropriate clinical management of BAP1 germline variant carriers and their families, including genetic counseling and surveillance for new tumors. Methods We collated germline variant status, tumor diagnoses, and information on BAP1 immunohistochemistry or loss of somatic heterozygosity on 106 published and 75 unpublished BAP1 germline variant-positive families worldwide to better characterize the genotypes and phenotypes associated with the BAP1-TPDS. Tumor spectrum and ages of onset were compared between missense and null variants. All statistical tests were two-sided. Results The 181 families carried 140 unique BAP1 germline variants. The collated data confirmed the core tumor spectrum associated with the BAP1-TPDS and showed that some families carrying missense variants can exhibit this phenotype. A variety of noncore BAP1-TPDS -associated tumors were found in families of variant carriers. Median ages of onset of core tumor types were lower in null than missense variant carriers for all tumors combined (P < .001), mesothelioma (P < .001), cutaneous melanoma (P < .001), and nonmelanoma skin cancer (P < .001). Conclusions This analysis substantially increases the number of pathogenic BAP1 germline variants and refines the phenotype. It highlights the need for a curated registry of germline variant carriers for proper assessment of the clinical phenotype of the BAP1-TPDS and pathogenicity of new variants, thus guiding management of patients and informing areas requiring further research.
This paper references
10.1016/j.canlet.2015.09.011
Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.
M. Cheung (2015)
10.1002/cjp2.86
Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma
N. Farquhar (2018)
10.1155/2017/1310478
Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
E. Pulford (2017)
10.1093/neuonc/now235
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas
G. Shankar (2017)
10.1002/gcc.7
Analysis of the exome aggregation consortium (ExAC) database suggests that the BAP1‐tumor predisposition syndrome is underreported in cancer patients
James B. Massengill (2018)
10.1016/j.febslet.2013.10.035
BAP1 is phosphorylated at serine 592 in S‐phase following DNA damage
Ziad M Eletr (2013)
10.1111/cge.12472
Germline BAP1 mutations predispose also to multiple basal cell carcinomas
A. de la Fouchardière (2015)
10.1016/J.YOPH.2011.03.038
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
T. Milman (2011)
10.1038/sj.onc.1201861
BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression
D. Jensen (1998)
10.1158/1541-7786.MCR-13-0111
A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma
Megan N Farley (2013)
BAP1 Tumor Predisposition Syndrome
R. Pilarski (2016)
10.1111/cge.12630
Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases
K. Rai (2016)
10.1002/gcc.22116
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma
L. Gossage (2014)
Ocular melanoma: an overview of the current status.
P. Jovanovic (2013)
10.1634/theoncologist.2015-0446
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Supriya K. Saha (2016)
10.1158/0008-5472.CAN-13-3109
Germline mutations in BAP1 impair its function in DNA double-strand break repair.
I. H. Ismail (2014)
10.1093/neuonc/nou223
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.
Q. Ostrom (2014)
10.1016/j.cancergen.2015.12.007
A novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer.
Kevin J. McDonnell (2016)
10.1073/pnas.1309085110
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
Helen Yu (2013)
Inactivation of BAP 1 / ASXL 2 DUB activity in cancer 1 The BAP 1 / ASXL 2 Histone H 2 A Deubiquitinase Complex Regulates Cell Proliferation and is Disrupted in Cancer *
Salima Daou (2015)
10.1016/j.ajhg.2013.04.012
Germline BAP1 mutations predispose to renal cell carcinomas.
Tatiana Popova (2013)
Surveillance Epidemology and End Results Program ( SEER )
NA HowladerN (1996)
10.1158/0008-5472.CAN-08-0365
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.
Karen H. Ventii (2008)
10.1093/neuonc/nox158
CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014
Q. Ostrom (2017)
10.1016/j.gcb.2010.07.016
Primary peritoneal mesothelioma: case series and literature review.
H. Sharma (2011)
10.1111/cge.12501
A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma
K.A.W. Wadt (2015)
10.1042/BST20160173
Molecular architecture of polycomb repressive complexes
Emily C. Chittock (2017)
10.1158/0008-5472.CAN-14-1328
Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Jinfei Xu (2014)
10.1371/journal.pgen.1005633
Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s
M. Carbone (2015)
10.1016/j.celrep.2016.05.096
NeuCode Proteomics Reveals Bap1 Regulation of Metabolism.
Joshua M. Baughman (2016)
10.21037/jgo.2016.03.05
BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype.
Humaid Al-Shamsi (2016)
10.1371/journal.pone.0035295
Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families
C. Njauw (2012)
10.1101/111039
Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the Clinical Genome Resource
Natasha T Strande (2017)
10.1016/j.ejca.2017.12.022
Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy.
P. Star (2018)
10.1158/0008-5472.CAN-14-0221
Deubiquitination of γ-tubulin by BAP1 prevents chromosome instability in breast cancer cells.
Reihaneh Zarrizi (2014)
10.1158/0008-5472.CAN-15-3371
Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations.
Yuwaraj Kadariya (2016)
10.1136/jmedgenet-2011-100156
Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
M. Abdel-Rahman (2011)
10.1128/MCB.00396-10
The Ubiquitin Carboxyl Hydrolase BAP1 Forms a Ternary Complex with YY1 and HCF-1 and Is a Critical Regulator of Gene Expression
Helen Yu (2010)
10.1002/gcc.22129
Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases
R. Pilarski (2014)
10.1038/nature22798
BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
A. Bononi (2017)
10.1002/humu.22965
UMD‐Predictor: A High‐Throughput Sequencing Compliant System for Pathogenicity Prediction of any Human cDNA Substitution
David Salgado (2016)
10.1158/0008-5472.CAN-17-2876
Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains.
H. Peng (2018)
10.1002/gcc.22473
Occurrence of BAP1 germline mutations in cutaneous melanocytic tumors with loss of BAP1‐expression: A pilot study
O. Cabaret (2017)
10.1093/annonc/mdt135
Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.
C. Ribeiro (2013)
10.1158/0008-5472.CAN-15-0295
Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
J. Ohar (2016)
10.1007/s00262-017-1991-1
Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment
G. Gezgin (2017)
10.1016/j.ophtha.2016.01.008
BAP1 Germline Mutations in Finnish Patients with Uveal Melanoma.
J. Turunen (2016)
10.1186/s12859-016-0917-9
Web-TCGA: an online platform for integrated analysis of molecular cancer data sets
Mario Deng (2016)
10.1007/s00401-015-1423-2
Primary leptomeningeal melanoma is part of the BAP1-related cancer syndrome
A. Fouchardière (2015)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1038/gim.2015.3
ERRATUM: Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder
Richards (2015)
10.1158/1078-0432.CCR-14-0330
Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer
M. Nickerson (2014)
10.1007/s12032-013-0541-8
Prognostic significance of BRCA1-associated protein 1 in colorectal cancer
Jianjun Tang (2013)
10.1007/s12253-013-9677-2
BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma
L. Arzt (2013)
10.1038/cdd.2017.95
Germline BAP1 mutations induce a Warburg effect
A. Bononi (2017)
10.1093/carcin/bgu227
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
F. Baumann (2015)
10.1038/ng.910
Germline mutations in BAP1 predispose to melanocytic tumors
T. Wiesner (2011)
10.1093/nar/gku274
The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex
Zongling Ji (2014)
10.1093/nar/gkw1121
COSMIC: somatic cancer genetics at high-resolution
S. Forbes (2017)
10.5271/SJWEH.1145
Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia.
Rebecca A Hyland (2007)
10.1186/s12920-018-0353-y
Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics
C. Ernst (2018)
10.1001/jamadermatol.2017.2330
Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature
A. Haugh (2017)
10.1038/srep18462
Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in enzymatic inactivation
S. Bhattacharya (2015)
10.1038/onc.2015.243
Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma
A. Napolitano (2016)
10.1016/j.celrep.2018.03.052
Systematic Analysis of Splice-Site-Creating Mutations in Cancer
R. Jayasinghe (2018)
10.1093/nar/gkx1153
ClinVar: improving access to variant interpretations and supporting evidence
M. Landrum (2018)
10.1074/jbc.M115.661553
The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer*♦
Salima Daou (2015)
10.1158/1078-0432.CCR-12-3886
Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
A. Hakimi (2013)
10.1016/S1470-2045(12)70584-3
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
P. Kapur (2013)
10.1016/j.pathol.2017.03.005
Germline BAP1 mutations also predispose to cutaneous squamous cell carcinoma.
R. Rawson (2017)
10.1177/1010428317699111
Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer
Xiang-yu Wang (2017)



This paper is referenced by
10.1097/PAS.0000000000001565
The Separation of Benign and Malignant Mesothelial Proliferations
A. Churg (2020)
10.1007/s12022-019-09595-0
Loss of BAP1 in Pheochromocytomas and Paragangliomas Seems Unrelated to Genetic Mutations
Valeria Maffeis (2019)
10.1093/ajcp/aqaa176
BAP1-Mutated Clear Cell Renal Cell Carcinoma.
A. Gallan (2020)
10.1136/jclinpath-2019-206271
Thirty-six-year-old woman with a liver mass: diagnosis hidden in history
S. Vos (2020)
10.3389/fonc.2020.00101
Preclinical Models of Malignant Mesothelioma
J. Testa (2020)
10.1016/j.jdcr.2020.04.018
An adolescent with uveal melanoma and BAP1 tumor predisposition syndrome
Kelly Z. Young (2020)
10.1001/jamaophthalmol.2019.3941
Intraocular Metastasis in Unilateral Multifocal Uveal Melanoma Without Melanocytosis or Germline BAP1 Mutations.
M. Durante (2019)
10.1038/s41525-020-0121-8
Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer
Megan E. Tesch (2020)
10.1158/0008-5472.CAN-20-0592
Loss of BAP1 Leads to More YAPing in Pancreatic Cancer
R. Brekken (2020)
10.1016/j.jtho.2019.07.002
Brief Report: Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
M. Zauderer (2019)
10.1136/jmedgenet-2020-107098
Loss-of-function variants in POT1 predispose to uveal melanoma.
Vaishnavi Nathan (2020)
10.1002/1878-0261.12651
Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival
Lisa Quetel (2020)
10.5772/intechopen.91752
Emerging Drug Therapies for Mesothelioma
D. B. Oien (2020)
10.3390/cancers12041007
Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1
L. Pastorino (2020)
10.1016/j.ajo.2020.12.005
Uveal Melanoma in BAP1 Tumor Predisposition Syndrome: Estimation of Risk.
Nakul Singh (2020)
10.2340/00015555-3267
BAP1 Tumour Predisposition Syndrome: A New Mutation in One Family.
F. Satolli (2019)
10.3390/ijms21197172
Iris Colour and the Risk of Developing Uveal Melanoma
Laurien E Houtzagers (2020)
10.1186/s12885-019-6226-8
BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy
Bianca Costa Soares de Sá (2019)
10.1038/s41568-020-0265-y
Tumour predisposition and cancer syndromes as models to study gene–environment interactions
M. Carbone (2020)
GENOTYPE – PHENOTYPE CORRELATIONS IN CUTANEOUS MELANOMA PATIENTS CARRIER OF THE MITF p . E 318 K PATHOGENIC VARIANT
A. Szent-Gyorgyi (2019)
10.1016/j.annpat.2020.02.022
Les cancers du rein héréditaires vus par le pathologiste en 2020
V. Verkarre (2020)
10.21037/tlcr.2019.11.15
Mesothelioma developing in carriers of inherited genetic mutations.
Yoshie Yoshikawa (2020)
10.3390/medicines7080044
Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets
U. Testa (2020)
10.21037/tlcr.2020.02.01
How asbestos and other fibers cause mesothelioma.
G. Gaudino (2020)
10.1038/s41525-020-00157-6
Functional characterisation guides classification of novel BAP1 germline variants
J. H. Hong (2020)
10.1093/jnci/djaa047
Germline MBD4 Mutations and Predisposition to Uveal Melanoma
Anne-Céline Derrien (2020)
10.1016/j.eururo.2019.06.015
Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights.
Maria I Carlo (2019)
10.3322/caac.21572
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
M. Carbone (2019)
10.1126/sciadv.aax1738
BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers
Jeffim N. Kuznetsov (2019)
10.1038/s41436-020-0783-8
Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG)
M. Li (2020)
10.1016/J.MRREV.2019.03.001
Genetic predisposition for malignant mesothelioma: A concise review.
M. Betti (2019)
10.1016/j.thorsurg.2020.08.005
The Molecular Basis of Malignant Pleural Mesothelioma.
Benjamin Wadowski (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar